Sara Nayeem

Sara NayeemPartner

Sara Nayeem, M.D. is a Principal with New Enterprise Associates, a diversified venture capital firm with $13B in committed capital. Sara joined NEA's healthcare team in January 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana and Cydan and as a board observer for Epizyme, Omthera and Zyngenia. She has also been involved in NEA's investments in Tesaro, Prosensa, and 3-V Biosciences. Prior to joining NEA, Sara was an Associate with Merrill Lynch's Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her M.D. (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biological Sciences from Harvard University.